Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:rifampin
|
| gptkbp:activities |
inhibits bacterial RNA synthesis
|
| gptkbp:appointed_by |
oral tablet
intravenous injection |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associated_with |
drug resistance
|
| gptkbp:brand |
gptkb:Rifampin
Rifabutin Rifapentine |
| gptkbp:can_be_used_with |
gptkb:beer
gptkb:ethambutol gptkb:isoniazid gptkb:pyrazinamide certain herbal supplements |
| gptkbp:clinical_trial |
combination therapies
new formulations |
| gptkbp:contraindication |
liver disease
hypersensitivity to rifamycins |
| gptkbp:developed_by |
gptkb:Amycolatopsis_rifamycinica
gptkb:Eli_Lilly_and_Company antimycobacterial therapy |
| gptkbp:discovered_by |
1950s
|
| gptkbp:duration |
6 months for tuberculosis
up to 12 months for leprosy |
| gptkbp:established |
gptkb:Mycobacterium_tuberculosis
Mycobacterium leprae |
| gptkbp:excretion |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
rifamycins
|
| gptkbp:interacts_with |
gptkb:warfarin
oral contraceptives antiretroviral drugs |
| gptkbp:is_analyzed_in |
antibiotic resistance
leprosy treatment strategies tuberculosis treatment strategies |
| gptkbp:is_available_in |
tablets
capsules injectable form |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_effective_against |
fungal infections
viral infections |
| gptkbp:is_monitored_by |
kidney function
liver function |
| gptkbp:is_used_for |
treating leprosy
treating tuberculosis |
| gptkbp:pharmacokinetics |
metabolized in the liver
highly protein-bound |
| gptkbp:side_effect |
hepatotoxicity
orange discoloration of bodily fluids |
| gptkbp:social_structure |
macrocyclic lactone
|
| gptkbp:suitable_for |
pregnant women
breastfeeding women |